BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, November 28, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» TMEM97 as a new therapeutic target for the treatment of neuropathic pain
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
TMEM97 as a new therapeutic target for the treatment of neuropathic pain
Jan. 16, 2024
No Comments
The σ2 receptor (σ2R) has been recently identified as transmembrane protein 97 (TMEM97), and ligands of σ2R/TMEM97 have previously shown the ability to alleviate mechanical hypersensitivity in mouse models of neuropathic pain.
BioWorld Science
Neurology/psychiatric